- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model NEW YORK ( TheStreet) -- Cubist Pharmaceuticals (Nasdaq: CBST) hit a new 52-week high Thursday as it is currently trading at $47.99, above its previous 52-week high of $47.97 with 414,832 shares traded as of 2:05 p.m. ET. Average volume has been 772,800 shares over the past 30 days. Cubist has a market cap of $3.04 billion and is part of the health care sector and drugs industry. Shares are up 20.3% year to date as of the close of trading on Wednesday. Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company has a P/E ratio of 31.2, below the average drugs industry P/E ratio of 32.4 and above the S&P 500 P/E ratio of 17.7.